The Lymphoma Academic Research Organisation

This study tests a combination of three drugs (glofitamab, venetoclax, and zanubrutinib) in people with a fast-growing type of lymphoma called mantle cell lymphoma. It includes patients whose cancer has come back or not responded to treatment, as well as newly diagnosed patients …

This study tests a new drug called epcoritamab, given with two other drugs (lenalidomide and rituximab), for people whose primary CNS lymphoma has returned or stopped responding to treatment. About 60 adults will take part to see if the combination shrinks tumors and how safe it …

This study tests whether a combination of two drugs, mosunetuzumab and lenalidomide, works better than standard treatments for people with marginal zone lymphoma that has come back or stopped responding to therapy. About 260 adults who have had 1 to 3 prior treatments will be ran…

This study tests whether adding the experimental drug lacutamab to standard chemotherapy helps people with a rare type of blood cancer (peripheral T-cell lymphoma) that has returned or stopped responding to treatment. About 56 adults whose cancer cells have a specific marker call…

This study reviews medical records from about 250 adults with large B-cell lymphoma who received the drug Glofitamab through a special access program in France. Researchers want to see how well the drug controls the cancer and what side effects occur, especially in patients whose…

This study is a registry that collects information from women who have a rare type of lymphoma linked to breast implants. The goal is to learn more about the disease and how it responds to treatment. Researchers in France and Belgium will track 150 participants over time.

This study is a French registry that collects information on up to 5,000 people with blood cancers who are eligible for CAR-T cell therapy. It tracks how long patients live, how well the treatment works, and how quickly they receive it. The goal is to gather real-world data to im…

This study is testing new drugs or drug combinations for people with peripheral T-cell lymphoma that has come back or stopped responding to treatment. The main goal is to gather early information on safety and effectiveness to help design larger, more focused future studies. Abou…